Team Publications
At Bioquantis, we are committed to pushing the boundaries of cardiovascular research through cutting-edge data analytics and artificial intelligence. Our work is published in leading peer-reviewed journals, including JACC, European Heart Journal, Circulation, reflecting our contribution to the evolution of clinical epidemiology and cardiology. Through rigorous scientific studies, we enhance the understanding of cardiac and coronary artery disease, atrial fibrillation, and ischemic risk stratification, ensuring our innovations translate into real-world impact for patient care.
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
2019;73:1362-1364
Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG
Read ArticleNew-onset atrial fibrillation in chronic coronary syndrome in the CLARIFY registry
2023:ehad556
Gautier A, Picard F, Ducrocq G, Elbez Y, Fox KM, Ferrari R, Ford I, Tardif JC, Tendera M, Steg PG
Read ArticleAssociation of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients
2019 ;73:3281-3291
Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM, Röther J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG
Read ArticleExternal applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
2018;39:750-757a
Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG
Read ArticlePotential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry
2018;39:3855-3863
Vidal-Petiot E, Sorbets E, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG
Read ArticleTiming of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban)
2017;136:1895-1907
Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack C Jr, Wiviott SD, Elbez Y, Sabatine MS, Steg PG
Read Article